MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Oncomed Pharmaceuticals Company Profile (NASDAQ:OMED)

Consensus Ratings for Oncomed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $20.33 (69.59% upside)

Analysts' Ratings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Leerink SwannBoost Price TargetMarket Perform$11.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells FargoInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Piper JaffraySet Price TargetBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014($0.30)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.13)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Oncomed Pharmaceuticals (NASDAQ:OMED)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)$1.15($0.21)
Q2 20161($0.87)($0.87)($0.87)
Q3 20163($0.75)($0.58)($0.66)
Q4 20161($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)
Dividend History for Oncomed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Oncomed Pharmaceuticals (NASDAQ:OMED)
DateHeadline
06/27/16 09:50 AMNext Weeks Broker Price Targets For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Fiscal Standard
06/26/16 10:09 AMONCOMED PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/25/16 09:20 AMOncomed Pharmaceuticals Inc's Stock Is Sell After Today's Gap Down - Engelwood Daily
06/24/16 03:40 PMONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/23/16 06:09 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Current Analyst Ratings - Fiscal Standard
06/23/16 06:09 PMStrong Buy Calls Count For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) At 6 - Investor Newswire
06/21/16 07:23 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : June 21, 2016 -
06/20/16 05:28 PMThe Pros And Cons Of Pfizer Separating GEP
06/10/16 07:26 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : OMED-US : June 10, 2016 -
06/08/16 06:02 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Decreased -8.14%: Facebook Inc (NASDAQ:FB), AT&T, Inc. (NYSE ... - KC Register
06/08/16 06:02 PMONCOMED PHARMACEUTICALS INC. (NASDAQ:OMED) Financial Condition Compared to S&P 500 - CML News
06/07/16 08:21 AMSprint Corporation (NYSE:S) Went Up 1.59%: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), eFuture Holding Inc ... - KC Register
06/06/16 05:34 PMOncoMed Pharmaceuticals (NASDAQ:OMED) Tumbled -6.25%: Apple Inc. (NASDAQ:AAPL), Telefonaktiebolaget LM ... - KC Register
06/06/16 05:34 PMOncoMed Pharma (OMED) Presents Data on Four Clinical-Stage Programs at ASCO 2016 - StreetInsider.com
06/06/16 07:18 AMOncoMed Management to Present at Two Upcoming Investment Conferences - [at noodls] - June 6, 2016 REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing ...
06/05/16 05:38 PMOncoMed Pharmaceuticals Inc.: OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and ... - The Wall Street Transcript
06/05/16 08:08 AMOncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting - [at noodls] - June 5, 2016 First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 ...
06/04/16 08:30 AMStock Review and Earnings Check on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - HNN
06/04/16 08:30 AMWere Analysts Bullish Oncomed Pharmaceuticals Inc (NASDAQ:OMED) This Week? - HNN
06/03/16 06:05 PMJust Published: "Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Review, H1 2016"
06/02/16 06:00 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, ...Stock Trending Up: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)The PostOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Latest Broker ViewsRisers & Fallersall 44 news articles »
05/31/16 05:53 PMOncoMed Pharmaceuticals Inc. (OMED) Jumps 7.66% on May 30 - Equities.com - OncoMed Pharmaceuticals Inc. (OMED) Jumps 7.66% on May 30Equities.comOncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 7.66% to $14.62, representing a gain of $1.04 per share. Some 144,967 shares traded hands on 1,192 trades, compared ...and more »
05/31/16 09:30 AMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Stock Update & Estimates - Stock Tick Tock - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to post earnings of $-0.71 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/30/16 12:10 AMOncomed Pharmaceuticals Incorporated (NASDAQ:OMED) Shorted Shares Increased By 24.17% - HNN - Oncomed Pharmaceuticals Incorporated (NASDAQ:OMED) Shorted Shares Increased By 24.17%HNNOncoMed Pharmaceuticals, Inc. is a clinical development-stage biopharmaceutical company. The company has a market cap of $476.88 million. The Firm focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics.Is it Time to Cash in Profits on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)Franklin IndependentOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) EPS Estimate At $-0.7Enterprise Leaderall 6 news articles »
05/29/16 11:14 PMThe Top 5 Growth Equity Managers in the Mid-West for 2016 - [at Investopedia] - Learn about growth equity firms in the Midwest, along with the growth of private funding firms and managers due to the technology boom.
05/27/16 07:46 PMEarnings Review and Stock Rundown for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Wall Street Hints and News - Earnings Review and Stock Rundown for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting OncoMed Pharmaceuticals, Inc.and more »
05/26/16 07:31 PMOncomed Pharmaceuticals Inc 14.4% Potential Upside Now Implied by Mizuho - DirectorsTalk Interviews - BenzingaOncomed Pharmaceuticals Inc 14.4% Potential Upside Now Implied by MizuhoDirectorsTalk InterviewsOncomed Pharmaceuticals Inc with TICKER NASDAQ:OMED had its stock rating noted as 'Reiterated' with the recommendation being set at 'BUY' yesterday by analysts at Mizuho. Oncomed Pharmaceuticals Inc are listed in the Health Care sector within ...Mizuho Raises OncoMed Pharma's Price Target To $16BenzingaMizuho Increases Oncomed Pharmaceuticals Inc (OMED) Price Target to $16.00Community Financial NewsOncomed Pharmaceuticals Inc (OMED) is Reiterated by Mizuho to Buy, Raises Price Target to $ 16Market DigestRisers & Fallers -Share Trading Newsall 6 news articles »
05/23/16 04:28 PMETF’s with exposure to OncoMed Pharmaceuticals, Inc. : May 23, 2016 -
05/23/16 12:21 PMStock Highlights: Gilead Sciences Inc. (NASDAQ:GILD), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Symantec ... - KC Register - Stock Highlights: Gilead Sciences Inc. (NASDAQ:GILD), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Symantec ...KC RegisterOn 5 May, OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) reported Revenues for the first quarter 2016 totaled $6.4 million, as compared to $9.7 million in the first quarter of 2015. The decrease in revenue over the same period in 2015 was primarily due to ...and more »
05/21/16 12:09 AMOncoMed Pharmaceuticals Inc. (OMED) Jumps 5.21% on May 20 - Equities.com - OncoMed Pharmaceuticals Inc. (OMED) Jumps 5.21% on May 20Equities.comOncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.21% to $12.72, representing a gain of $0.63 per share. Some 98,513 shares traded hands on 822 trades, compared with an ...and more »
05/20/16 07:02 PMPancreatic Ductal Adenocarcinoma Pipeline Report 2016 - Review of 24 Companies & Drug Profiles - Research and Markets - LLC Incyte Corporation Inovio Pharmaceuticals, Inc. MedImmune, LLC Medisyn Technologies, Inc. Merck & Co., Inc. Nerviano Medical Sciences S.r.l. OncoMed Pharmaceuticals, Inc. Oryx GmbH & Co. KG Sillajen Biotherapeutics Tara Immuno-Oncology Therapeutics LLC ...
05/18/16 11:30 AMLeerink Swann Maintains Oncomed Pharmaceuticals Inc to Market Perform with Price Target $13.00 - Trade Calls - Leerink Swann Maintains Oncomed Pharmaceuticals Inc to Market Perform with Price Target $13.00Trade CallsBrokerage firm Leerink Swann Maintains its rating on Oncomed Pharmaceuticals Inc(NASDAQ:OMED). In a research note issued to the investors, the brokerage major Raises the price-target to $13.00 per share. The shares have been rated Market Perform.and more »
05/17/16 11:56 PMOncoMed Pharmaceuticals Inc. (OMED) Jumps 6.15% on May 16 - Equities.com - OncoMed Pharmaceuticals Inc. (OMED) Jumps 6.15% on May 16Equities.comOncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.15% to $12.08, representing a gain of $0.7 per share. Some 155,721 shares traded hands on 1,484 trades, compared with ...and more »
05/17/16 12:16 PMOncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 06:47 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Basic Consolidated EPS At $-2.8442 - RealistInvestor.com - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Basic Consolidated EPS At $-2.8442RealistInvestor.comThe yearly basic consolidated EPS for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for the period ended 2015-12-31 was $-2.8442. For the quarter ended 2015-12-31 the basic consolidated EPS was $-2.8442. Earnings per share is the portion of the ...
05/16/16 06:47 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Broker Price Targets For The Coming Week - Share Trading News - OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, ...and more »
05/16/16 12:29 PMResearch report covers the Regenerative Medicine Market share and Growth, 2016-2026 - Some of the key participating global players in regenerative medicine market are OncoMed Pharmaceuticals, BrainCells, Five Prime Therapeutics, Pieris AG, Tyrx Pharma, Aldagen, Histogenics, Fate Therapeutics, iZumi Bio, Neurologix, Inc., Cellerant ...
05/14/16 12:45 AMOncoMed Pharmaceuticals Inc. (OMED) Jumps 5.37% on May 13 - Equities.com - OncoMed Pharmaceuticals Inc. (OMED) Jumps 5.37% on May 13Equities.comOncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Friday May 13 as the stock popped 5.37% to $11.38, representing a gain of $0.58 per share. Some 124,080 shares traded hands on 1,294 trades, compared with ...and more »
05/10/16 07:43 PMBiotechnology Volatile Stocks: Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV), OncoMed Pharmaceuticals, Inc ... - KC Register - Biotechnology Volatile Stocks: Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV), OncoMed Pharmaceuticals, Inc ...KC RegisterOn May 05, OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) reported first quarter financial results. Revenues for the first quarter 2016 totaled $6.4 million, as compared to $9.7 million in the first quarter of 2015. The decrease in revenue over the same ...and more »
05/10/16 12:24 AMOncoMed Pharmaceuticals Inc. (OMED) Jumps 12.4% on May 09 - Equities.com - OncoMed Pharmaceuticals Inc. (OMED) Jumps 12.4% on May 09Equities.comOncoMed Pharmaceuticals Inc. (OMED) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 12.4% to $11.51, representing a gain of $1.27 per share. Some 174,978 shares traded hands on 1,475 trades, compared ...and more »
05/09/16 07:38 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : OMED-US : May 9, 2016 -
05/06/16 08:08 PMEarnings Outlook on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - B.O.D.Y Confidential - Earnings Outlook on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)B.O.D.Y ConfidentialAnalysts and investors will be anticipating OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)'s next earnings release which is expected to be posted on or around 2016-08-08. Sell-side research firms on Wall Street are expecting that the company will post ...and more »
05/06/16 08:08 PMBRIEF-Oncomed Pharmaceuticals reports Q1 loss per share $0.90 - Reuters - BRIEF-Oncomed Pharmaceuticals reports Q1 loss per share $0.90ReutersMay 5 Oncomed Pharmaceuticals Inc. * Oncomed pharmaceuticals announces first quarter 2016 financial results. * Q1 loss per share $0.90. * Q1 revenue $6.4 million versus $9.7 million. * Existing cash is anticipated to fund company operations through q1 ...
05/06/16 08:08 PMOncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results - Nasdaq - OncoMed Pharmaceuticals Announces First Quarter 2016 Financial ResultsNasdaqREDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics, today reported first quarter financial ...and more »
05/05/16 08:34 PMOncoMed Pharmaceuticals Inc.: OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results - The Wall Street Transcript - Web Breaking NewsOncoMed Pharmaceuticals Inc.: OncoMed Pharmaceuticals Announces First Quarter 2016 Financial ResultsThe Wall Street TranscriptREDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics, today reported first quarter financial ...Broker Roundup For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)Share Trading NewsOncomed Pharmaceuticals Inc (OMED) PT Raised to $13.00 at Leerink SwannWeb Breaking NewsOncomed Pharmaceuticals Inc (OMED) Releases Earnings Results, Misses Expectations By $-0.15 EPSMarket DigestB.O.D.Y Confidential -Money Morningall 7 news articles »
05/05/16 05:57 PMOncoMed reports 1Q loss -
05/05/16 03:11 PMOncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results - [at noodls] - May 5, 2016 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT Highlights AACR Presentations - Including Novel GITRL-Fc Candidate Clinical Data on Vantictumab, ...
05/05/16 06:07 AMQ1 2016 OncoMed Pharmaceuticals Inc Earnings Release - Time Not Supplied -
04/28/16 03:05 PMBig Pharma grooves $20 billion M&A dance with 2 Bay Area biotechs -
04/04/16 02:22 PMOncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : April 4, 2016 -
About Oncomed Pharmaceuticals

Oncomed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OMED
  • CUSIP:
Key Metrics:
  • Previous Close: $11.99
  • 50 Day Moving Average: $12.64
  • 200 Day Moving Average: $12.88
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $363.27M
  • Current Quarter EPS Consensus Estimate: $-3.29 EPS
Additional Links:
Oncomed Pharmaceuticals (NASDAQ:OMED) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha